Latest Updates on the Serotonergic System in Depression and Anxiety

Overview

Journal Front Synaptic Neurosci

Date 2023 May 25

PMID 37228487

Authors

Jianwen Lin

Wenxin Liu

Jing Guan

Jianing Cui

Ruolin Shi

Lu Wang

Dong Chen

Yi Liu

Affiliations

Soon will be listed here.

Abstract

Psychiatric disorders are among the leading causes of global health burden, with depression and anxiety being the most disabling subtypes. The two common disorders, depression and anxiety, usually coexist and are pathologically polygenic with complicated etiologies. Current drug-based therapies include selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, and 5-hydroxytryptamine partial agonists. However, these modalities share common limitations, such as slow onset and low efficacy, which is why potential mechanistic insights for new drug targets are needed. In this review, we summarize recent advances in brain localization, pathology, and therapeutic mechanisms of the serotonergic system in depression and anxiety.

Citing Articles

Rotenone Induces Parkinsonism with Constipation Symptoms in Mice by Disrupting the Gut Microecosystem, Inhibiting the PI3K-AKT Signaling Pathway and Gastrointestinal Motility.

Liu L, Zhao Y, Yang W, Fan Y, Han L, Sheng J Int J Mol Sci. 2025; 26(5).

PMID: 40076704 PMC: 11899888. DOI: 10.3390/ijms26052079.

Redefining Roles: A Paradigm Shift in Tryptophan-Kynurenine Metabolism for Innovative Clinical Applications.

Tanaka M, Szabo A, Vecsei L Int J Mol Sci. 2024; 25(23).

PMID: 39684480 PMC: 11640972. DOI: 10.3390/ijms252312767.

Effect of a Web-Based Heartfulness Program on the Mental Well-Being, Biomarkers, and Gene Expression Profile of Health Care Students: Randomized Controlled Trial.

Thimmapuram J, Patel K, Bhatt D, Chauhan A, Madhusudhan D, Bhatt K JMIR Bioinform Biotechnol. 2024; 5:e65506.

PMID: 39680432 PMC: 11686021. DOI: 10.2196/65506.

Targeting serotonin receptors with phytochemicals - an in-silico study.

Elalouf A, Rosenfeld A, Maoz H Sci Rep. 2024; 14(1):30307.

PMID: 39638796 PMC: 11621125. DOI: 10.1038/s41598-024-76329-6.

Design and Synthesis of Potential Multi-Target Antidepressants: Exploration of 1-(4-(7-Azaindole)-3,6-dihydropyridin-1-yl)alkyl-3-(1-indol-3-yl)pyrrolidine-2,5-dione Derivatives with Affinity for the Serotonin Transporter.

Wrobel M, Chodkowski A, Siwek A, Satala G, Bojarski A, Dawidowski M Int J Mol Sci. 2024; 25(20).

PMID: 39457057 PMC: 11508649. DOI: 10.3390/ijms252011276.

References

Razakarivony O, Newman-Tancredi A, Zimmer L . Towards in vivo imaging of functionally active 5-HT receptors in schizophrenia: concepts and challenges. Transl Psychiatry. 2021; 11(1):22. PMC: 7791062. DOI: 10.1038/s41398-020-01119-3. View

Martiny K . Novel Augmentation Strategies in Major Depression. Dan Med J. 2017; 64(4). View

Wang Q, Dong X, Hu T, Qu C, Lu J, Zhou Y . Constitutive Activity of Serotonin Receptor 6 Regulates Human Cerebral Organoids Formation and Depression-like Behaviors. Stem Cell Reports. 2020; 16(1):75-88. PMC: 7815944. DOI: 10.1016/j.stemcr.2020.11.015. View

Guzel T, Mirowska-Guzel D . The Role of Serotonin Neurotransmission in Gastrointestinal Tract and Pharmacotherapy. Molecules. 2022; 27(5). PMC: 8911970. DOI: 10.3390/molecules27051680. View

Karayol R, Medrihan L, Warner-Schmidt J, Fait B, Rao M, Holzner E . Serotonin receptor 4 in the hippocampus modulates mood and anxiety. Mol Psychiatry. 2021; 26(6):2334-2349. PMC: 8275670. DOI: 10.1038/s41380-020-00994-y. View

Stamm S, Gruber S, Rabchevsky A, Emeson R . The activity of the serotonin receptor 2C is regulated by alternative splicing. Hum Genet. 2017; 136(9):1079-1091. PMC: 5873585. DOI: 10.1007/s00439-017-1826-3. View

Quintero-Villegas A, Valdes-Ferrer S . Central nervous system effects of 5-HT receptors: a potential target for neurodegenerative diseases. Mol Med. 2022; 28(1):70. PMC: 9208181. DOI: 10.1186/s10020-022-00497-2. View

Carr G, Lucki I . The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology (Berl). 2010; 213(2-3):265-87. PMC: 3374933. DOI: 10.1007/s00213-010-2097-z. View

Liu Q, Yao X, Gao S, Li R, Li B, Yang W . Role of 5-HT receptors in neuropathic pain: potential therapeutic implications. Pharmacol Res. 2020; 159:104949. DOI: 10.1016/j.phrs.2020.104949. View

10.

Olie J, Kasper S . Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007; 10(5):661-73. DOI: 10.1017/S1461145707007766. View

11.

Madsen K, Torstensen E, Holst K, Haahr M, Knorr U, Frokjaer V . Familial risk for major depression is associated with lower striatal 5-HT₄ receptor binding. Int J Neuropsychopharmacol. 2014; 18(1). PMC: 4368872. DOI: 10.1093/ijnp/pyu034. View

12.

Gelenberg A . A review of the current guidelines for depression treatment. J Clin Psychiatry. 2010; 71(7):e15. DOI: 10.4088/JCP.9078tx1c. View

13.

Borroto-Escuela D, Ambrogini P, Chruscicka B, Lindskog M, Crespo-Ramirez M, Hernandez-Mondragon J . The Role of Central Serotonin Neurons and 5-HT Heteroreceptor Complexes in the Pathophysiology of Depression: A Historical Perspective and Future Prospects. Int J Mol Sci. 2021; 22(4). PMC: 7919680. DOI: 10.3390/ijms22041927. View

14.

Kohler-Forsberg K, Ozenne B, Larsen S, Poulsen A, Landman E, Dam V . Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding. A NeuroPharm-1 study. Transl Psychiatry. 2022; 12(1):273. PMC: 9276803. DOI: 10.1038/s41398-022-02034-5. View

15.

Nautiyal K, Hen R . Serotonin receptors in depression: from A to B. F1000Res. 2017; 6:123. PMC: 5302148. DOI: 10.12688/f1000research.9736.1. View

16.

Cipriani A, Furukawa T, Salanti G, Chaimani A, Atkinson L, Ogawa Y . Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128):1357-1366. PMC: 5889788. DOI: 10.1016/S0140-6736(17)32802-7. View

17.

Calhoun C, Lattouf C, Lewis V, Barrientos H, Donaldson S . Chronic mild stress induces differential depression-like symptoms and c-Fos and 5HT1A protein levels in high-anxiety female Long Evans rats. Behav Brain Res. 2022; 438:114202. PMC: 9990717. DOI: 10.1016/j.bbr.2022.114202. View

18.

Cipriani A, Zhou X, Del Giovane C, Hetrick S, Qin B, Whittington C . Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet. 2016; 388(10047):881-90. DOI: 10.1016/S0140-6736(16)30385-3. View

19.

Browne C, Jacobson M, Lucki I . Novel Targets to Treat Depression: Opioid-Based Therapeutics. Harv Rev Psychiatry. 2020; 28(1):40-59. DOI: 10.1097/HRP.0000000000000242. View

20.

Wesolowska A . Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data. Pharmacol Rep. 2010; 62(4):564-77. DOI: 10.1016/s1734-1140(10)70315-7. View